Table 1 Breast Cancer Cases, TNM Classification, and Characteristics.

From: Novel breast cancer screening: combined expression of miR-21 and MMP-1 in urinary exosomes detects 95% of breast cancer without metastasis

No.

Age

(years)

Body Weight

(kg)

BMI

(kg/m2)

TNM classification*

Stage

Patho

Expression Levels of miR-21 (2ΔCt)#

Expression Levels of MMP-1/CD63##

1

61

110

40.4

T2N0M0

II

scirrhous ca.

0.11

1.78

2

59

53

19.5

TisN0M0

0

microinvasive-

0.26

1.02

3

36

67

24.3

T2N0M0

II

solid tub. ca.

0.09

1.70

4

56

49

19.1

T1N0M0

II

scirrhous ca.

1.04

2.00

5

46

53

21.5

T2N0M0

I

solid tub. ca.

0.37

1.08

6

40

68

26.9

T3N1M0

IIIA

pap-tub.ca.

0.18

0.76

7

52

52

20.8

T1N1M0

IIA

scirrhous ca.

0.32

1.09

8

52

63

26.1

T2N1M0

IIB

scirrhous ca.

0.22

0.85

9

48

54

20.4

T1N0M0

I

scirrhous ca.

0.30

1.84

10

74

69

25.3

T2N0M0

II

mucinous ca.

0.08

3.04

11

49

56

22.4

T1N0M0

I

scirrhous ca.

0.00

23.20

12

48

62

22.5

T1N0M0

I

pap-tub. ca.

0.06

3.56

13

46

65

22.8

T1 N0 M0

I

ductal ca. in situ

0.01

2.25

14

47

54

20.1

T3 N3 M0

IIIC

scirrhous ca

0.01

3.91

15

47

70

27.0

T1 N0 M0

I

scirrhous ca

0.36

2.23

16

45

57

22.7

Tis N0 M0

0

inv lob ca

0.26

6.78

17

74

57

24.3

T3 N0 M0

II

scirrhous ca

0.23

3.90

18

52

50

16.7

T3N0M0

IIIA

inv. lobular ca

0.49

1.53

19

72

61

26.8

T3N1M0

IIIA

mucinous ca

0.41

0.78

20

45

50

19.8

T1cN3M0

IIIA

inv. ductal ca

2.27

1.02

21

46

52

20.6

T1N3M0

IIIA

scirrhous ca

1.48

0.92

22

35

58

20.1

T2N0M0

I

mucinous ca

2.22

0.11

      

Median

(95% CI)

0.26

(0.20–0.73)

1.74

(0.86–5.08)

  1. *TNM classification; Pathological diagnosis; ca: carcinoma; tub: tubular; pap: papillary.
  2. #Number indicates the relative expression levels, that is microRNA copies by RT-PCR in patients divided the mean number of microRNA copies in healthy controls.
  3. ##Number indicates the relative expression levels of MMP-1/CD63, that was measured by western blotting with both antibodies.